FY2029 Earnings Forecast for Geron Issued By HC Wainwright

Geron Co. (NASDAQ:GERN) – HC Wainwright issued their FY2029 EPS estimates for shares of Geron in a research report issued on Wednesday, February 26th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings per share of $0.60 for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Other equities research analysts have also recently issued reports about the stock. B. Riley cut shares of Geron from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $3.50 to $2.00 in a research report on Thursday. Needham & Company LLC lowered their price target on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Scotiabank reduced their price objective on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. Stifel Nicolaus decreased their target price on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Barclays reissued an “overweight” rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Stock Up 8.1 %

Shares of GERN opened at $1.74 on Friday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53. Geron has a 12-month low of $1.46 and a 12-month high of $5.34. The firm has a fifty day moving average price of $2.97 and a 200-day moving average price of $3.80. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million.

Institutional Investors Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP bought a new position in Geron in the third quarter worth about $200,268,000. Nvest Financial LLC bought a new position in shares of Geron during the 4th quarter worth approximately $693,000. Janus Henderson Group PLC lifted its position in Geron by 140.0% during the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after acquiring an additional 13,163,889 shares during the last quarter. Barclays PLC boosted its stake in Geron by 114.9% in the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock valued at $5,902,000 after acquiring an additional 694,931 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Geron in the third quarter worth $1,102,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.